Why Senseonics Skyrocketed 340% in the First Half of 2021
Shares of Senseonics Holdings (NYSEMKT: SENS) skyrocketed 340% in the first half of 2021. The stock vaulted more than 500% higher by mid-February, but gave up some of those gains.
One key early catalyst for Senseonics was a positive coverage decision in January by health insurer EmblemHealth for the Eversense continuous glucose-monitoring (CGM) system used by individuals with diabetes. That was just the beginning of the good news for the company, though.
In June, Senseonics reported positive results from a clinical study of its version of the Eversense device that can remain implanted for 180 days. The company's current version of the CGM system marketed in the U.S. can be used for up to 90 days.
Source Fool.com